Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Elastic
ESTC
|
+$386M |
| 2 |
Mercado Libre
MELI
|
+$307M |
| 3 |
Nu Holdings
NU
|
+$265M |
| 4 |
Shopify
SHOP
|
+$254M |
| 5 |
Roblox
RBLX
|
+$253M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Beyond Meat
BYND
|
+$232M |
| 2 |
Li Auto
LI
|
+$219M |
| 3 |
Illumina
ILMN
|
+$187M |
| 4 |
Albemarle
ALB
|
+$178M |
| 5 |
Ferrari
RACE
|
+$147M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 29.03% |
| 2 | Healthcare | 24.31% |
| 3 | Technology | 16.9% |
| 4 | Communication Services | 11.22% |
| 5 | Financials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Globus Medical
GMED
$11.2B
| $3.82M | ﹤0.01% |
64,077
| – | – |
|
252
Texas Instruments
TXN
$261B
| $3.72M | ﹤0.01% |
24,059
| – | – |
|
|
SAGE
253
DELISTED
Sage Therapeutics
SAGE
| $3.58M | ﹤0.01% |
91,395
+2,949
| +3% | +$114K |
|
254
Alector
ALEC
$199M
| $3.52M | ﹤0.01% |
371,837
+17,345
| +5% | +$188K |
|
255
HUTCHMED
HCM
$2.17B
| $3.45M | ﹤0.01% |
389,818
+24,839
| +7% | +$313K |
|
256
GitLab
GTLB
$6.58B
| $3.31M | ﹤0.01% |
64,583
-19,732
| -23% | -$1.15M |
|
|
MTLS
257
Materialise
MTLS
$396M
| $2.87M | ﹤0.01% |
268,000
| – | – |
|
258
CarMax
KMX
$8.26B
| $2.78M | ﹤0.01% |
42,148
-2,449
| -5% | -$224K |
|
|
API
259
Agora
API
$377M
| $2.7M | ﹤0.01% |
744,300
| – | – |
|
260
Adicet Bio
ACET
$74.7M
| $2.58M | ﹤0.01% |
11,352
| – | – |
|
|
RUBY
261
DELISTED
Rubius Therapeutics, Inc
RUBY
| $2.1M | ﹤0.01% |
4,853,773
-52,305
| -1% | -$39.2K |
|
|
CLLS
262
Cellectis
CLLS
$285M
| $1.81M | ﹤0.01% |
788,837
-92,095
| -10% | -$279K |
|
263
Golub Capital BDC
GBDC
$3.42B
| $1.51M | ﹤0.01% |
122,100
| – | – |
|
264
Transmedics
TMDX
$2.91B
| $1.47M | ﹤0.01% |
35,271
+1,544
| +5% | +$67.1K |
|
265
MaxCyte
MXCT
$126M
| $1.31M | ﹤0.01% |
+202,800
| New | +$1.13M |
|
266
Sixth Street Specialty
TSLX
$1.81B
| $1.3M | ﹤0.01% |
79,500
| – | – |
|
267
Agnico Eagle Mines
AEM
$90.5B
| $1.12M | ﹤0.01% |
26,423
+23,023
| +677% | +$987K |
|
268
Newmont
NEM
$119B
| $1.09M | ﹤0.01% |
25,959
+3,172
| +14% | +$148K |
|
269
WEC Energy
WEC
$35.1B
| $1.01M | ﹤0.01% |
11,353
-7,643
| -40% | -$781K |
|
270
Spire Global
SPIR
$555M
| $935K | ﹤0.01% |
108,256
| – | – |
|
271
Novanta
NOVT
$6.29B
| $918K | ﹤0.01% |
7,938
+352
| +5% | +$48K |
|
272
Exelon
EXC
$47B
| $856K | ﹤0.01% |
22,861
-5,591
| -20% | -$247K |
|
273
Ameren
AEE
$30.1B
| $837K | ﹤0.01% |
10,390
-2,541
| -20% | -$232K |
|
274
American Tower
AMT
$80.4B
| $835K | ﹤0.01% |
3,890
+326
| +9% | +$83.8K |
|
275
Xencor
XNCR
$1.55B
| $833K | ﹤0.01% |
32,055
+1,398
| +5% | +$40K |
|
Similar funds
Baillie Gifford & Co's Q3 2022 Portfolio in Review
As of Q3 2022, Baillie Gifford & Co held 506 positions worth $97B, down 0.53% from $97.5B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Baillie Gifford & Co's Q3 2022 filing shows 13 new, 130 increased, 158 reduced and 20 closed positions. Its largest new stake was Elastic: 4,847,733 shares worth $348M. The largest sale was Beyond Meat, an estimated $232M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 29% of assets, up from 27% a quarter earlier, followed by Healthcare and Technology.
- Baillie Gifford & Co's largest Q3 2022 buy was Elastic: 4,847,733 shares worth $348M.
- Baillie Gifford & Co added most to Mercado Libre in Q3 2022, an estimated $307M increase.
- Baillie Gifford & Co's biggest Q3 2022 reduction was Beyond Meat, cutting an estimated $232M.
- Baillie Gifford & Co fully exited Zai Lab in Q3 2022, selling an estimated $25.5M.
- Baillie Gifford & Co's ten largest holdings make up 37% of its $97B portfolio in Q3 2022.
- Baillie Gifford & Co opened 13 new positions and closed 20 in Q3 2022.
- Baillie Gifford & Co's portfolio value fell 0.53% quarter-over-quarter to $97B.
Based on Baillie Gifford & Co's 13F filing for Q3 2022, filed 27 Oct 2022.